# Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

> **NCT00468611** · PHASE3 · TERMINATED · sponsor: **BioMS Technology Corp.** · enrollment: 510 (actual)

## Conditions studied

- Multiple Sclerosis, Secondary Progressive

## Interventions

- **DRUG:** MBP8298

## Key facts

- **NCT ID:** NCT00468611
- **Lead sponsor:** BioMS Technology Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-09
- **Target enrollment:** 510 (ACTUAL)
- **Why stopped:** Negative efficacy results of the MAESTRO-01 study
- **Last updated:** 2009-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00468611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00468611, "Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00468611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*